Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaTony Mok, Masahiro Fukuoka, Alison Armour et al.|New England Journal of Medicine|2009Cited by 8.2k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Geoffrey R. Oxnard et al.|New England Journal of Medicine|2020Cited by 835
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsAlexander Drilon, Robert C. Doebele, Salvatore Siena et al.|The Lancet Oncology|2019Cited by 537
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerGeoffrey R. Oxnard, Myung‐Ju Ahn, J.C.-H. Yang et al.|Annals of Oncology|2020Cited by 443
Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinomaKouya Shiraishi, Takashi Kohno, Yukinori Okada et al.|Nature Communications|2016Cited by 58